Tekla Capital Management’s Epizyme, Inc EPZM Stock Holding History

Tekla Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-207,752	Closed	-$3.34M	–	226
2020 Q2	$3.34M	Hold	207,752	–	–	0.13%	129
2020 Q1	$3.22M	Sell	207,752 -145,350	-41%	-$3.12M	0.15%	111
2019 Q4	$8.69M	Sell	353,102 -46,502	-12%	-$690K	0.33%	72
2019 Q3	$4.12M	Hold	399,604	–	–	0.18%	95
2019 Q2	$5.01M	Buy	399,604 +110,200	+38%	+$1.42M	0.2%	91
2019 Q1	$3.59M	Sell	289,404 -96,468	-25%	-$1.08M	0.15%	113
2018 Q4	$2.38M	Sell	385,872 -99,453	-20%	-$760K	0.1%	120
2018 Q3	$5.14M	Hold	485,325	–	–	0.19%	90
2018 Q2	$6.58M	Hold	485,325	–	–	0.25%	83
2018 Q1	$8.62M	Buy	485,325 +29,325	+6%	+$495K	0.34%	69
2017 Q4	$5.72M	Hold	456,000	–	–	0.22%	81
2017 Q3	$8.69M	Buy	456,000 +175,000	+62%	+$2.67M	0.31%	62
2017 Q2	$4.24M	Sell	281,000 -81,000	-22%	-$1.22M	0.16%	93
2017 Q1	$6.21M	Sell	362,000 -38,000	-10%	-$506K	0.24%	76
2016 Q4	$4.84M	Hold	400,000	–	–	0.21%	81
2016 Q3	$3.94M	Hold	400,000	–	–	0.15%	94
2016 Q2	$4.1M	Hold	400,000	–	–	0.17%	100
2016 Q1	$4.85M	Buy	+400,000	New	+$4.05M	0.21%	84
2015 Q4	–	Sell	-256,700	Closed	-$3.3M	–	158
2015 Q3	$3.3M	Buy	256,700 +56,700	+28%	+$1.14M	0.12%	122
2015 Q2	$4.8M	Hold	200,000	–	–	0.17%	87
2015 Q1	$3.76M	Buy	+200,000	New	+$4.13M	0.15%	91
2014 Q4	–	Sell	-141,262	Closed	-$3.83M	–	114
2014 Q3	$3.83M	Buy	141,262 +71,100	+101%	+$2.21M	0.18%	94
2014 Q2	$2.18M	Buy	+70,162	New	+$1.65M	0.2%	53

Other funds holding EPZM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Tekla Capital Management's EPZM Position: Q3 2020 in Review

Tekla Capital Management sold out of Epizyme, Inc (EPZM) in Q3 2020, closing a stake of 207,752 shares — an estimated $3.34M sold.

Tekla Capital Management first reported a position in EPZM in Q2 2014 and held it in 23 quarters. The position peaked at $8.69M in Q3 2017. 151 funds tracked by Wall St. Rank hold EPZM as of Q3 2020.

Tekla Capital Management reported no remaining Epizyme, Inc position as of Q3 2020 after selling out during the quarter.
Tekla Capital Management sold 207,752 Epizyme, Inc shares in Q3 2020, an estimated $3.34M.
Tekla Capital Management first reported a position in Epizyme, Inc in Q2 2014 and held it in 23 quarters.
Tekla Capital Management's Epizyme, Inc position peaked at $8.69M in Q3 2017.
151 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2020.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.